Pages Menu
FacebookTwitterPinterestRss
Categories Menu

CTD Holdings


.
PATIENT & TRIAL INFORMATION
.

Dr. Sharon Hrynkow
Medical Professional Liasion

sharon.hrynkow@cyclodex.com

Shannon Reedy
Patient Liaison, U.S. Based

shannon.reedy@hotmail.com

Jackie Imrie
Patient Liaison, UK Based

jackie@jicltd.co.uk



This page is dedicated to news and information about CTD Holding’s therapies for use in Niemann-Pick Disease Types C (NPC).
Information is released as it becomes available.

ABOUT CTD HOLDINGS, INC.     GLOSSARY OF TERMS



CTD Holdings Enrolls First Patient in
US Phase I Clinical Trial of Trappsol(R) Cyclo(TM)
for Treatment of Niemann-Pick Disease Type C

.
CLICK HERE FOR COMPLETE ANOUNCEMENT

09/28/2017 jjb

CTD Holdings Announces Approval of Clinical Trial
Application to Conduct Phase I/II Clinical Study
of Trappsol(R) Cyclo(TM) in Patients with
Niemann-Pick Type C Disease in Israel

.
CLICK HERE FOR COMPLETE ANNOUNCEMENT


CTD Holdings Announces First Patient Dosed in
Phase I/II Clinical Trial to Evaluate Trappsol(R)
Cyclo(TM) in Niemann-Pick Disease Type C

.
CLICK HERE FOR COMPLETE ANNOUNCEMENT

07/20/2017 jjb

CTD Holdings Ships Additional
Trappsol® Cyclo™ to Brazil

.
FULL PRESS RELEASE

06/27/2017 jjb

CTD Holdings Enrolls First Patient in European

Phase I/II Clinical Trial of Trappsol® Cyclo™ 

for Treatment of Niemann-Pick Disease Type C

.
CLICK HERE FOR COMPLETE ANNOUNCEMENT

06/21/2017 jjb

CTD WEBINAR

Clinical Program Update on Trappsol® Cyclo™

Drug Development Program for NPC Treatment

.
NPC CLINICAL TRIAL WEBINAR

6/13/2017 jjb

CTD Holdings to Host Webinar

to Provide Update on Trappsol® Cyclo™

Drug Development Program for NPC Treatment

.
CLICK HERE FOR MORE INFORMATION

5/16/2017 jjb

CTD Holdings Initiates Recruitment for
Phase I/II Clinical Study in Europe of Trappsol® Cyclo™
for Treatment of Niemann-Pick Disease Type C

CLICK HERE FOR FULL ANNOUNCEMENT

03/21/2017 jjb

CTD Holdings Closes
$2 Million Private Placement

CLICK HERE FOR FULL ANNOUNCEMENT

02/23/2017 jjb

CTD Holdings Presents Compassionate Use Data
on Trappsol(R) Cyclo(TM) to Treat
Niemann-Pick Disease Type C and Provides Update
on Progress of U.S. and EU Clinical Trials at
13th Annual WORLDSymposium

CLICK HERE FOR FULL ANNOUNCEMENT

02/20/2017 jjb

FDA Grants Fast Track Designation for
Trappsol (R) Cyclo(TM) in
Drug Development Program for NPC

CLICK HERE FOR FULL ANNOUNCEMENT

01/17/2017 jjb

CTD Holdings Files Clinical Trial Application
with Italian Drug Agency to Continue Advancing
Trappsol(R) Cyclo(TM) 
Drug Development Program
to Treat Niemann-Pick Disease Type C

CLICK HERE FOR FULL ANNOUNCEMENT

12/22/2016 jjb

CTD HOLDINGS IV TRAPPSOL CYCLO STUDY

The NNPDF Central Office has received notice that
CTD’s US trial parameters for the IV Trappsol Cyclo study in NPC
are now published at Clinical Trials.Gov.


CTD HOLDINGS PRESS RELEASE

CTD Holdings Announces MHRA Approval of Clinical Trial
Application for Treatment of NPC With Trappsol(R) Cyclo(TM)

CLICK HERE FOR FULL RELEASE


09/29/2016 jjb